American Association of Clinical Chemistry (AACC) is a global scientific and medical professional organization dedicated to clinical laboratory science and its application to healthcare. Their leadership in education, advocacy and collaboration helps lab professionals adapt to change and do what they do best: provide vital insight and guidance so patients get the care they need. Their online publication "Clinical Laboratory News" features articles and educational materials with many benefits for all researchers around the globe. We found the following article, Managing Supply Chain Disruptions During the COVID-19 Pandemic, to be particularly beneficial during the recent pandemic and its aftermath. We've included a few excerpts below, as well as the link for the full text.
Managing Supply Chain Disruptions During the COVID-19 Pandemic Bench Matters: March 2021 Authors: Jack A. Maggiore, PhD, MT(ASCP) and Jonathan Bakst, MBA, MHS, PA (ASCP) // Date: MAR.1.2021 // Source: Clinical Laboratory News
Let’s be honest. The emergency disaster relief policies that labs had in place at the start of 2020 were high level placeholders required by our accrediting agencies. Very few—if any—of us had plans for responding to a global pandemic that seriously disrupted supply chains worldwide. Instead of strategizing and planning, we found ourselves primarily responding, trying to maintain our operations and serve our customers. Like most everyone, Loyola Medicine, a three-hospital system based in the Chicago suburb of Maywood, Illinois, struggled with these issues. We started in-house SARS-CoV-2 testing on March 19, 2020, and by the end of the year had performed 120,000 polymerase chain reaction (PCR) tests using six testing platforms. We performed another 6,300 antibody tests, including on 4,000 colleagues. We’ve learned many valuable lessons this past year and, in this article, describe some of our key takeaways.- Just-in-time inventory doesn’t work for pandemics, but stockpiling has its limitations beyond essential personal protective equipment (PPE).
- Cutting personnel in response to low test volumes is short-sighted.
- Keep training staff.
- Fear of modifying a method, thereby making it a laboratory developed test (LDT), shouldn’t automatically rule out this option.
- Vendor loyalty might bring products into a lab, but when that company experiences supply disruptions, not having relationships with multiple vendors could prove problematic.
- Build supplier redundancies.
- Recognize when it’s time to execute backup.
- Develop systems for outsourcing nonessential testing.
- Look hard at all primary and essential methods to determine if a sound, validated backup exists, and detail the logistics required to implement this solution.
- Audit and revise labs’ pandemic response plans.